See more : Mirai Works Inc. (6563.T) Income Statement Analysis – Financial Results
Complete financial analysis of Acceleron Pharma Inc. (XLRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acceleron Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vinx Corp. (3784.T) Income Statement Analysis – Financial Results
- TricornTech Taiwan Corporation (6909.TWO) Income Statement Analysis – Financial Results
- PT Dyandra Media International Tbk (DYAN.JK) Income Statement Analysis – Financial Results
- Bio Science Animal Health Public Company Limited (BIS.BK) Income Statement Analysis – Financial Results
- Bimetal Bearings Limited (BIMETAL.BO) Income Statement Analysis – Financial Results
Acceleron Pharma Inc. (XLRN)
About Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 173.92M | 153.95M | 103.90M | 89.73M | 68.58M | 58.40M | 50.90M | 36.05M | 35.32M | 32.71M |
| General & Administrative | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Other Expenses | 85.91M | 56.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 40.86M |
| Cost & Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 42.36M |
| Interest Income | 2.87M | 10.71M | 5.57M | 2.55M | 1.85M | 512.00K | 83.00K | 39.00K | 91.00K | 17.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 922.00K | 2.09M | 1.53M | 1.82M |
| Depreciation & Amortization | 3.85M | 3.94M | 3.75M | 2.83M | 1.68M | 1.18M | 1.12M | 915.00K | 1.29M | 3.13M |
| EBITDA | -162.16M | -120.98M | -115.15M | -105.60M | -55.31M | -62.72M | -49.22M | -18.89M | -29.76M | 41.22M |
| EBITDA Ratio | -175.27% | -163.50% | -823.04% | -783.30% | -199.18% | -346.57% | -336.38% | -33.01% | -195.10% | 50.95% |
| Operating Income | -167.31M | -136.45M | -124.41M | -109.98M | -66.11M | -60.88M | -50.46M | 6.95M | -28.89M | 38.56M |
| Operating Income Ratio | -180.83% | -184.40% | -889.24% | -815.84% | -238.04% | -336.40% | -344.89% | 12.15% | -189.39% | 47.65% |
| Total Other Income/Expenses | 1.30M | 11.53M | 5.52M | 1.56M | 9.12M | -3.02M | -795.00K | -28.85M | -3.69M | -2.29M |
| Income Before Tax | -166.01M | -124.92M | -118.90M | -108.42M | -56.99M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Income Before Tax Ratio | -179.42% | -168.83% | -849.82% | -804.26% | -205.21% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| Income Tax Expense | 21.00K | -62.00K | -27.00K | 32.00K | 24.00K | -3.02M | 127.00K | -26.76M | -2.16M | -468.00K |
| Net Income | -166.03M | -124.86M | -118.87M | -108.45M | -57.01M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Net Income Ratio | -179.45% | -168.74% | -849.62% | -804.50% | -205.30% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| EPS | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.73 |
| EPS Diluted | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.58 |
| Weighted Avg Shares Out | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 20.95M |
| Weighted Avg Shares Out (Dil) | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 22.97M |
ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acceleron Pharma Inc. - XLRN
Activist Investor Thinks Merck Undervalues Acceleron Buy
Core PCE Inflation Stays at Record-High in August
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
Merck & Co., Inc. (MRK) Merck to Acquire Acceleron Pharma Conference Call (Transcript)
Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma
Acceleron Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Acceleron Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XLRN
Shareholder Alert: Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fair Price in its transaction with Merck
Merck buying Acceleron Pharma in $11.5B deal
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
Source: https://incomestatements.info
Category: Stock Reports